Suven Pharma Q3 Results: Net profit surges 78% to Rs 83 crore, revenue up 40%

PE firm Advent backed Suven Pharma net profit rose 78% year-on-year (YoY) to Rs 83.3 crore in Q3FY25 compared to Rs 46.8 crore in the corresponding period of the previous year.

Revenue grew 40% YoY to Rs 307.2 crore in Q3FY25 driven by doubling of CDMO business driven by R&D and business development efforts.

Gross margins for the quarter stood at 71.5% and adjusted EBITDA margins stood at 38.7%.

The Hyderabad-based company said it is seeing strong demand across stages on the back of secular macro tailwinds.
It said two molecules added this quarter in which one molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules.

It also said a previously highlighted positive readout on Phase III molecule has now met the primary endpoint for a second indication and onboarded a new strategic customer – one of the top five global pharma leaders for early-to-mid-phase projects.

Stock Trading

Maximise Returns by Investing in the Right Companies

By – The Economic Times, Get Certified By India’s Top Business News Brand
Stock Trading

Market 104: Options Trading: Kickstart Your F&O Adventure

By – Saketh R, Founder- QuickAlpha, Full Time Options Trader
Stock Trading

Technical Analysis for Everyone – Technical Analysis Course

By – Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities
Stock Trading

Stock Markets Made Easy

By – elearnmarkets, Financial Education by StockEdge
Stock Trading

Renko Chart Patterns Made Easy

By – Kaushik Akiwatkar, Derivative Trader and Investor
Stock Trading

Candlesticks Made Easy: Candlestick Pattern Course

By – elearnmarkets, Financial Education by StockEdge
Stock Trading

Market 101: An Insight into Trendlines and Momentum

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

Market 103: Mastering Trends with RMI and Techno-Funda Insights

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

Dow Theory Made Easy

By – Vishal Mehta, Independent Systematic Trader
Stock Trading

ROC Made Easy: Master Course for ROC Stock Indicator

By – Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading

RSI Made Easy: RSI Trading Course

By – Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading

Heikin Ashi Trading Tactics: Master the Art of Trading

By – Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading

RSI Trading Techniques: Mastering the RSI Indicator

By – Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading

Introduction to Technical Analysis & Candlestick Theory

By – Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert

“We continue to make business development efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision,’ said Vivek Sharma, executive chairman.”Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth,” Sharma added.

Forrás: eredeti cikk

Ezt a cikket a SasFly.net hozta neked. Jogi kérdésekben hazai ügyekben az fabianlaw.hu, nemzetközi jogi képviselet esetén a amerikaiugyved.hu csapata áll rendelkezésedre.